They cannot replace healthy lifestyle habits which forms the core of any diabetes management or weight loss program
Mounjaro is a newer medication that acts on both GLP-1 and GIP receptors, making it more effective than Ozempic for weight loss and blood sugar control in some patients
Summary: Berberine is not a GLP-1 receptor agonist and does not bind to or activate GLP-1 receptors like prescription medications such as semaglutide or liraglutide
Common issues may include nausea, constipation, diarrhea, reflux, bloating, reduced appetite, or fatigue
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
doi:10.1152/ajpendo.2001.281.1.E155 Garber AJ